Discontinued — last reported Q3 '25
Roivant Sciences Non-Controlling Interests increased by 8.5% to $765.04M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 53.1%, from $499.59M to $765.04M. Over 5 years (FY 2020 to FY 2025), Non-Controlling Interests shows an upward trend with a 25.9% CAGR.
An increase suggests the company has expanded its consolidated operations through partially-owned subsidiaries, while a decrease may indicate buyouts of minority stakes.
This represents the portion of equity in a subsidiary not attributable, directly or indirectly, to the parent company. I...
Common in large conglomerates or companies with complex joint venture structures; peers often report this as a small fraction of total equity.
noncontrolling_interests| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $234.22M | $390.39M | $381.54M | $382.00M | $371.28M | $353.55M | $471.62M | $449.82M | $423.41M | $377.10M | $494.82M | $479.95M | $459.98M | $427.09M | $346.50M | $499.59M | $470.27M | $443.13M | $704.97M | $765.04M |
| QoQ Change | — | +66.7% | -2.3% | +0.1% | -2.8% | -4.8% | +33.4% | -4.6% | -5.9% | -10.9% | +31.2% | -3.0% | -4.2% | -7.2% | -18.9% | +44.2% | -5.9% | -5.8% | +59.1% | +8.5% |
| YoY Change | — | — | — | — | +58.5% | -9.4% | +23.6% | +17.8% | +14.0% | +6.7% | +4.9% | +6.7% | +8.6% | +13.3% | -30.0% | +4.1% | +2.2% | +3.8% | +103.5% | +53.1% |